Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to treat bacterial infections. It resembles penicillin and hence is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, and gonorrhea. The global cephalosporin market is estimated to reach $1,99,754 million by 2023 from $77,764 million in 2016, growing at a CAGR of 14.4% from 2017 to 2023. Research Beam Model: Research Beam Product ID: 2708311 5370 USD New
Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection) - Global Opportunity Analysis and Industry Forecast, 2017-2023

 
  • Category : Healthcare
  • Published On : November  2017
  • Pages : 240
 
 

Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to treat bacterial infections. It resembles penicillin and hence is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, and gonorrhea. The global cephalosporin market is estimated to reach $1,99,754 million by 2023 from $77,764 million in 2016, growing at a CAGR of 14.4% from 2017 to 2023.

The major factors that contribute to the growth of the cephalosporin market include increase in R&D activities to develop highly efficient & safe drugs; upsurge in use of combination therapies; and rise in incidence of pneumonia, tonsillitis, bronchitis, and gonorrhea. Moreover, increased approvals of drugs and growth in awareness about various infections & antibiotic resistance propel the market growth. However, side effects associated with cephalosporin and development of drug-resistant bacterial strains impede the market growth. Conversely, increase in mergers and acquisition among key vendors and development of combination therapies in untapped market are anticipated to provide potential opportunities for the market growth.

The global cephalosporin market is segmented on the basis of generation, type, route of drug administration, application, and region. Based on generation, the market is divided into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. By type, it is bifurcated into branded and generics.

Depending on route of drug administration, it is classified into injection and oral. The applications covered in the study include respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors.
  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the market through 2016–2023 that helps identify the upcoming market opportunities.
  • Recent industry trends and developments and the future opportunities are also covered.
  • Extensive knowledge about the key market players and their strategies is provided.
  • Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.

Key Market Segments

By Generation

  • First-generation Cephalosporin
  • Second-generation Cephalosporin
  • Third-generation Cephalosporin
  • Fourth-generation Cephalosporin  
  • Fifth-generation Cephalosporin

By Type

  • Branded
  • Generics
  • By Route of Drug Administration
  • Injection
  • Oral

By Application

  • Respiratory Tract Infection
  • Skin Infection
  • Ear Infection
  • Urinary Tract Infection
  • Sexually Transmitted Infection
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key market players

  • The key players operating in this market include
  • Allergan Plc
  • Bristol-Myers Squibb Company
  • Lupin Limited
  • Sanofi
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2015-2017

3.2.2.1. Competitive intelligence and strategies of companies

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. Surge in incidence of infectious diseases
3.3.1.2. Increase in R&D activities for the development of combination drugs
3.3.1.3. Rise in funding for the development of antibiotics

3.3.2. Restraints

3.3.2.1. Side effects associated with cephalosporins
3.3.2.2. Antibiotic resistance to cephalosporins

3.3.3. Opportunities

3.3.3.1. Lucrative opportunities in the emerging economies

3.4. MARKET SHARE ANALYSIS, 2016
3.5. PORTERS FIVE FORCES ANALYSIS
3.6. NOVEL MOLECULES IN CEPHALOSPORIN MARKET

3.6.1. CEFTAZIDIME
3.6.2. CEFUROXIME

3.7. COMBINATION THERAPIES IN CEPHALOSPORIN MARKET

CHAPTER 4 CEPHALOSPORIN MARKET, BY GENERATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. FIRST-GENERATION CEPHALOSPORIN

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. SECOND-GENERATION CEPHALOSPORIN

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. THIRD-GENERATION CEPHALOSPORIN

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. FOURTH-GENERATION CEPHALOSPORIN

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. FIFTH-GENERATION CEPHALOSPORIN

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

CHAPTER 5 CEPHALOSPORIN MARKET, BY TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. BRANDED CEPHALOSPORIN DRUGS

5.2.1. Market size and forecast

5.3. GENERIC CEPHALOSPORIN DRUGS

5.3.1. Market size and forecast

CHAPTER 6 CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. CEPHALOSHORIN INJECTIONS

6.2.1. Market size and forecast

6.3. ORAL CEPHALOSPORIN DRUGS

6.3.1. Market size and forecast

CHAPTER 7 CEPHALOSPORIN MARKET, BY APPLICATION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. RESPIRATORY TRACT INFECTION

7.2.1. Market size and forecast

7.3. SKIN INFECTION

7.3.1. Market size and forecast

7.4. EAR INFECTION

7.4.1. Market size and forecast

7.5. URINARY TRACT INFECTION

7.5.1. Market size and forecast

7.6. SEXUALLY TRANSMITTED INFECTION

7.6.1. Market size and forecast

7.7. OTHERS

7.7.1. Market size and forecast

CHAPTER 8 CEPHALOSPORIN MARKET, BY REGION

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Growth factors and opportunities
8.2.3. North America cephalosporin market by country

8.2.3.1. U.S.

8.2.3.1.1. U.S. cephalosporin market by generation
8.2.3.1.2. U.S. cephalosporin market by type
8.2.3.1.3. U.S. cephalosporin market by route of drug administration
8.2.3.1.4. U.S. cephalosporin market by application

8.2.3.2. Canada

8.2.3.2.1. Canada cephalosporin market by generation
8.2.3.2.2. Canada cephalosporin market by type
8.2.3.2.3. Canada cephalosporin market by route of drug administration
8.2.3.2.4. Canada cephalosporin market by application

8.2.3.3. Mexico

8.2.3.3.1. Mexico cephalosporin market by generation
8.2.3.3.2. Mexico cephalosporin market by type
8.2.3.3.3. Mexico cephalosporin market by route of drug administration
8.2.3.3.4. Mexico cephalosporin market by application

8.2.4. North America cephalosporin market by generation
8.2.5. North America cephalosporin market by type
8.2.6. North America cephalosporin market by route of drug administration
8.2.7. North America cephalosporin market by application

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Growth factors and opportunities
8.3.3. Europe cephalosporin market by country

8.3.3.1. Germany

8.3.3.1.1. Germany cephalosporin market by generation
8.3.3.1.2. Germany cephalosporin market by type
8.3.3.1.3. Germany cephalosporin market by route of drug administration
8.3.3.1.4. Germany cephalosporin market by application

8.3.3.2. France

8.3.3.2.1. France cephalosporin market by generation
8.3.3.2.2. France cephalosporin market by type
8.3.3.2.3. France cephalosporin market by route of drug administration
8.3.3.2.4. France cephalosporin market by application

8.3.3.3. UK

8.3.3.3.1. UK cephalosporin market by generation
8.3.3.3.2. UK cephalosporin market by type
8.3.3.3.3. UK cephalosporin market by route of drug administration
8.3.3.3.4. UK cephalosporin market by application

8.3.3.4. Italy

8.3.3.4.1. Italy cephalosporin market by generation
8.3.3.4.2. Italy cephalosporin market by type
8.3.3.4.3. Italy cephalosporin market by route of drug administration
8.3.3.4.4. Italy cephalosporin market by application

8.3.3.5. Spain

8.3.3.5.1. Spain cephalosporin market by generation
8.3.3.5.2. Spain cephalosporin market by type
8.3.3.5.3. Spain cephalosporin market by route of drug administration
8.3.3.5.4. Spain cephalosporin market by application

8.3.3.6. Rest of Europe

8.3.3.6.1. Rest of Europe cephalosporin market by generation
8.3.3.6.2. Rest of Europe cephalosporin market by type
8.3.3.6.3. Rest of Europe cephalosporin market by route of drug administration
8.3.3.6.4. Rest of Europe cephalosporin market by application

8.3.4. Europe cephalosporin market by generation
8.3.5. Europe cephalosporin market by type
8.3.6. Europe cephalosporin market by route of drug administration
8.3.7. Europe cephalosporin market by application

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Growth factors and opportunities
8.4.3. Asia-Pacific cephalosporin market by country

8.4.3.1. Japan

8.4.3.1.1. Japan cephalosporin market by generation
8.4.3.1.2. Japan cephalosporin market by type
8.4.3.1.3. Japan cephalosporin market by route of drug administration
8.4.3.1.4. Japan cephalosporin market by application

8.4.3.2. China

8.4.3.2.1. China cephalosporin market by generation
8.4.3.2.2. China cephalosporin market by type
8.4.3.2.3. China cephalosporin market by route of drug administration
8.4.3.2.4. China cephalosporin market by application

8.4.3.3. India

8.4.3.3.1. India cephalosporin market by generation
8.4.3.3.2. India cephalosporin market by type
8.4.3.3.3. India cephalosporin market by route of drug administration
8.4.3.3.4. India cephalosporin market by application

8.4.3.4. Australia

8.4.3.4.1. Australia cephalosporin market by generation
8.4.3.4.2. Australia cephalosporin market by type
8.4.3.4.3. Australia cephalosporin market by route of drug administration
8.4.3.4.4. Australia cephalosporin market by application

8.4.3.5. South Korea

8.4.3.5.1. South Korea cephalosporin market by generation
8.4.3.5.2. South Korea cephalosporin market by type
8.4.3.5.3. South Korea cephalosporin market by route of drug administration
8.4.3.5.4. South Korea cephalosporin market by application

8.4.3.6. Rest of Asia-Pacific

8.4.3.6.1. Rest of Asia-Pacific cephalosporin market by generation
8.4.3.6.2. Rest of Asia-Pacific cephalosporin market by type
8.4.3.6.3. Rest of Asia-Pacific cephalosporin market by route of drug administration
8.4.3.6.4. Rest of Asia-Pacific cephalosporin market by application

8.4.4. Asia-Pacific cephalosporin market by generation
8.4.5. Asia-Pacific cephalosporin market by type
8.4.6. Asia-Pacific cephalosporin market by route of drug administration
8.4.7. Asia-Pacific cephalosporin market by application

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Growth factors and opportunities
8.5.3. LAMEA cephalosporin market by country

8.5.3.1. Brazil

8.5.3.1.1. Brazil cephalosporin market by generation
8.5.3.1.2. Brazil cephalosporin market by type
8.5.3.1.3. Brazil cephalosporin market by route of drug administration
8.5.3.1.4. Brazil cephalosporin market by application

8.5.3.2. South Africa

8.5.3.2.1. South Africa cephalosporin market by generation
8.5.3.2.2. South Africa cephalosporin market by type
8.5.3.2.3. South Africa cephalosporin market by route of drug administration
8.5.3.2.4. South Africa cephalosporin market by application

8.5.3.3. Saudi Arabia

8.5.3.3.1. Saudi Arabia cephalosporin market by generation
8.5.3.3.2. Saudi Arabia cephalosporin market by type
8.5.3.3.3. Saudi Arabia cephalosporin market by route of drug administration
8.5.3.3.4. Saudi Arabia cephalosporin market by application

8.5.3.4. Rest of LAMEA

8.5.3.4.1. Rest of LAMEA cephalosporin market by generation
8.5.3.4.2. Rest of LAMEA cephalosporin market by type
8.5.3.4.3. Rest of LAMEA cephalosporin market by route of drug administration
8.5.3.4.4. Rest of LAMEA cephalosporin market by application
8.5.4. LAMEA cephalosporin market by generation

8.5.5. LAMEA cephalosporin market by type
8.5.6. LAMEA cephalosporin market by route of drug administration
8.5.7. LAMEA cephalosporin market by application

CHAPTER 9 COMPANY PROFILES

9.1. ALLERGAN PLC

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments

9.2. BRISTOL-MYERS SQUIBB COMPANY

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segment
9.2.4. Business performance

9.3. ELI LILLY AND COMPANY

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance

9.4. F. HOFFMANN-LA ROCHE AG

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments

9.5. GLAXOSMITHKLINE PLC

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance

9.6. LUPIN LIMITED (LUPIN PHARMACEUTICALS, INC.)

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance

9.7. MERCK & CO., INC.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments

9.8. PFIZER INC.

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments

9.9. SANOFI

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments

9.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 1. TOTAL COMMITTED PUBLIC FUNDING FOR ANTIBACTERIAL RESISTANCE RESEARCH BY JPIAMR COUNTRIES
TABLE 2. RECOMMENDED DOSAGE SCHEDULE FOR CEFTAZIMIDE
TABLE 3. CEFTAZIMIDE MARKET VALUE, 2016-2023 ($MILLION)
TABLE 4. AVERAGE SELLING PRICE ($) OF CEFTAZIMIDE
TABLE 5. RECOMMENDED DOSAGE SCHEDULE FOR CEFTIN
TABLE 6. CEFUROXIME MARKET VALUE, 2016-2023 ($MILLION)
TABLE 7. AVERAGE SELLING PRICE ($) OF CEFUROXIME
TABLE 8. NONCLASSIFIED AND COMBINATION CEPHALOSPORINS
TABLE 9. GLOBAL CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 10. FIRST-GENERATION CEPHALOSPORINS
TABLE 11. FIRST-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. SECOND-GENERATION CEPHALOSPORINS
TABLE 13. SECOND-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 14. THIRD-GENERATION CEPHALOSPORINS
TABLE 15. THIRD-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 16. FOURTH-GENERATION CEPHALOSPORINS
TABLE 17. FOURTH-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. FIFTH-GENERATION CEPHALOSPORINS
TABLE 19. FIFTH-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 21. BRANDED CEPHALOSPORIN DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. GENERIC CEPHALOSPORIN DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. GLOBAL CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 24. CEPHALOSPORIN DRUGS THAT ARE GIVEN AS INJECTION
TABLE 25. CEPHALOSPORIN INJECTIONS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. ORAL CEPHALOSPORIN DRUGS
TABLE 27. ORAL CEPHALOSPORIN DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 28. GLOBAL CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 29. CEPHALOSPORIN DRUGS USED TO TREAT RESPIRATORY TRACT INFECTION
TABLE 30. CEPHALOSPORIN MARKET FOR RESPIRATORY TRACT INFECTION, BY REGION, 2016-2023 ($MILLION)
TABLE 31. CEPHALOSPORIN DRUGS USED TO TREAT SKIN INFECTION
TABLE 32. CEPHALOSPORIN MARKET FOR SKIN INFECTION, BY REGION, 2016-2023 ($MILLION)
TABLE 33. CEPHALOSPORIN DRUGS USED TO TREAT EAR INFECTION
TABLE 34. CEPHALOSPORIN MARKET FOR EAR INFECTION, BY REGION, 2016-2023 ($MILLION)
TABLE 35. CEPHALOSPORIN DRUGS USED TO TREAT URINARY TRACT INFECTION
TABLE 36. CEPHALOSPORIN MARKET FOR URINARY TRACT INFECTION, BY REGION, 2016-2023 ($MILLION)
TABLE 37. CEPHALOSPORIN DRUGS USED TO TREAT INFECTION CAUSED DUE TO GONORRHOEA
TABLE 38. CEPHALOSPORIN MARKET FOR SEXUALLY TRANSMITTED INFECTION, BY REGION, 2016-2023 ($MILLION)
TABLE 39. CEPHALOSPORIN DRUGS USED FOR OTHER APPLICATIONS
TABLE 40. CEPHALOSPORIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 41. GLOBAL CEPHALOSPORIN MARKET, BY REGION ($MILLION), 2016-2023
TABLE 42. NORTH AMERICA CEPHALOSPORIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 43. U.S. CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 44. U.S. CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 45. U.S. CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 46. U.S. CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 47. CANADA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 48. CANADA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 49. CANADA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 50. CANADA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 51. MEXICO CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 52. MEXICO CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 53. MEXICO CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 54. MEXICO CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 55. NORTH AMERICA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 56. NORTH AMERICA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 57. NORTH AMERICA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 58. NORTH AMERICA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 59. TOP FIVE EUROPEAN COUNTRIES PER STI, 2000-2013
TABLE 60. EUROPE CEPHALOSPORIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 61. GERMANY CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 62. GERMANY CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 63. GERMANY CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 64. GERMANY CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 65. FRANCE CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 66. FRANCE CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 67. FRANCE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 68. FRANCE CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 69. UK CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 70. UK CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 71. UK CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 72. UK CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 73. ITALY CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 74. ITALY CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 75. ITALY CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 76. ITALY CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 77. SPAIN CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 78. SPAIN CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 79. SPAIN CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 80. SPAIN CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 81. REST OF EUROPE CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 82. REST OF EUROPE CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 83. REST OF EUROPE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 84. REST OF EUROPE CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 85. EUROPE CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 86. EUROPE CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 87. EUROPE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 88. EUROPE CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 89. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 90. JAPAN CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 91. JAPAN CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 92. JAPAN CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 93. JAPAN CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 94. CHINA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 95. CHINA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 96. CHINA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 97. CHINA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 98. INDIA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 99. INDIA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 100. INDIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 101. INDIA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 102. AUSTRALIA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 103. AUSTRALIA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 104. AUSTRALIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 105. AUSTRALIA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 106. SOUTH KOREA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 107. SOUTH KOREA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 108. SOUTH KOREA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 109. SOUTH KOREA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 110. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 111. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 112. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 113. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 114. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 115. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 116. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 117. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 118. LAMEA CEPHALOSPORIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 119. BRAZIL CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 120. BRAZIL CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 121. BRAZIL CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 122. BRAZIL CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 123. SOUTH AFRICA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 124. SOUTH AFRICA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 125. SOUTH AFRICA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 126. SOUTH AFRICA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 127. SAUDI ARABIA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 128. SAUDI ARABIA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 129. SAUDI ARABIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 130. SAUDI ARABIA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 131. REST OF LAMEA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 132. REST OF LAMEA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 133. REST OF LAMEA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 134. REST OF LAMEA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 135. LAMEA CEPHALOSPORIN MARKET, BY GENERATION, 2016-2023 ($MILLION)
TABLE 136. LAMEA CEPHALOSPORIN MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 137. LAMEA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2016-2023 ($MILLION)
TABLE 138. LAMEA CEPHALOSPORIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 139. ALLERGAN: COMPANY SNAPSHOT
TABLE 140. ALLERGEN: OPERATING SEGMENTS
TABLE 141. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 142. BRISTOL-MYERS SQUIBB: PRODUCT SEGMENTS
TABLE 143. LILLY: COMPANY SNAPSHOT
TABLE 144. LILLY OPERATING SEGMENTS
TABLE 145. ROCHE: COMPANY SNAPSHOT
TABLE 146. ROCHE: OPERATING SEGMENTS
TABLE 147. GSK: COMPANY SNAPSHOT
TABLE 148. GSK: OPERATING SEGMENTS
TABLE 149. LUPIN LIMITED: COMPANY SNAPSHOT
TABLE 150. LUPIN LIMITED: OPERATING SEGMENTS
TABLE 151. MERCK: COMPANY SNAPSHOT
TABLE 152. MERCK: OPERATING SEGMENTS
TABLE 153. PFIZER: COMPANY SNAPSHOT
TABLE 154. PFIZER: OPERATING SEGMENTS
TABLE 155. SANOFI: COMPANY SNAPSHOT
TABLE 156. SANOFI: OPERATING SEGMENTS
TABLE 157. TEVA: COMPANY SNAPSHOT
TABLE 158. TEVA: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. CEPHALOSPORIN MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES, 2015-2017 (%)
FIGURE 4. TOP COMPANIES AND THEIR STRATEGIES, 2015-2017
FIGURE 5. MARKET SHARE ANALYSIS, 2016
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF SUBSTITUTION
FIGURE 9. THREAT OF NEW ENTRANT
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. AGEADJUSTED DEATH RATES CAUSED DUE TO PNEUMONIA IN THE U.S., BY SEX, 2013
FIGURE 12. AGEADJUSTED DEATH RATES CAUSED DUE TO PNEUMONIA IN THE U.S., BY AGE GROUP, 2013
FIGURE 13. ALLERGAN: REVENUE, 2014-2016 ($MILLION)
FIGURE 14. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 15. BRISTOL-MYERS SQUIBB: REVENUE, 2014-2016 ($MILLION)
FIGURE 16. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY PRODUCT, 2016 (%)
FIGURE 17. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 18. LILLY: REVENUE, 2014-2016 ($MILLION)
FIGURE 19. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 20. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 21. ROCHE: NET SALES, 2014-2016 ($MILLION)
FIGURE 22. ROCHE: NET SALES BY SEGMENT, 2016 (%)
FIGURE 23. ROCHE: NET SALES BY GEOGRAPHY, 2016 (%)
FIGURE 24. GSK: REVENUE, 2014-2016 ($MILLION)
FIGURE 25. GSK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 26. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 27. LUPIN LIMITED: NET SALES, 2014-2016 ($MILLION)
FIGURE 28. LUPIN LIMITED: NET SALES BY GEOGRAPHY, 2016 (%)
FIGURE 29. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 30. MERCK: NET SALES BY SEGMENT, 2016 (%)
FIGURE 31. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 32. PFIZER: REVENUE, 2014-2016 ($MILLION)
FIGURE 33. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 34. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 35. SANOFI: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. SANOFI: NET SALES BY SEGMENT, 2016 (%)
FIGURE 37. SANOFI: NET SALES BY GEOGRAPHY, 2016 (%)
FIGURE 38. TEVA: REVENUE, 2014-2016 ($MILLION)
FIGURE 39. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 40. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)